Barclays
RLMD icon

Barclays’s Relmada Therapeutics RLMD Stock Holding History

Barclays’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Sell
51,234
-37,719
-42% -$264K ﹤0.01% 3392
2026
Q1 		$619K Buy
88,953
+28,953
+48% +$137K ﹤0.01% 3059
2025
Q4 		$290K Buy
60,000
+50,000
+500% +$168K ﹤0.01% 4141
2025
Q3 		$20.1K Buy
10,000
+9,999
+999,900% +$9.59K ﹤0.01% 4931
2025
Q2 		$1 Buy
+1
New +$1 ﹤0.01% 5202
2025
Q1 		– Sell
-145,999
Closed -$75.9K – 5512
2024
Q4 		$75.9K Hold
145,999
– – ﹤0.01% 4652
2024
Q3 		$473K Hold
145,999
– – ﹤0.01% 3815
2024
Q2 		$438K Hold
145,999
– – ﹤0.01% 3118
2024
Q1 		$679K Hold
145,999
– – ﹤0.01% 3396
2023
Q4 		$604K Hold
145,999
– – ﹤0.01% 3767
2023
Q3 		$438K Hold
145,999
– – ﹤0.01% 2876
2023
Q2 		$359K Buy
145,999
+131,161
+884% +$363K ﹤0.01% 2945
2023
Q1 		$33.5K Buy
14,838
+5,411
+57% +$18.7K ﹤0.01% 4539
2022
Q4 		$32.9K Buy
9,427
+2,326
+33% +$20.4K ﹤0.01% 4691
2022
Q3 		$263K Sell
7,101
-9,598
-57% -$266K ﹤0.01% 3059
2022
Q2 		$317K Buy
16,699
+14,999
+882% +$327K ﹤0.01% 3161
2022
Q1 		$46K Buy
+1,700
New +$35.2K ﹤0.01% 4150

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's RLMD Position: Q2 2026 in Review

Barclays reduced its Relmada Therapeutics (RLMD) stake by 42% in Q2 2026, selling an estimated $264K and leaving 51,234 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #3392.

Barclays first reported a position in RLMD in Q1 2022 and has held it in 17 quarters since. The position peaked at $679K in Q1 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Barclays held 51,234 shares of Relmada Therapeutics worth $355K as of Q2 2026.
  • Barclays sold 37,719 Relmada Therapeutics shares in Q2 2026, an estimated $264K.
  • Relmada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3392 holding.
  • Barclays first reported a position in Relmada Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Relmada Therapeutics position peaked at $679K in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.